Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
To test whether the addition of the COX-2 inhibitor, celecoxib, will decrease the gene
expression of CYP19 in breast cancers collected from postmenopausal women that receive
neoadjuvant exemestane.